Genetic polymorphisms of CYP2C8, CYP2C9 and CYP2C19 in Ecuadorian Mestizo and Spaniard populations: a comparative study

被引:18
作者
Vicente, Jorge [1 ]
Gonzalez-Andrade, Fabricio [2 ]
Soriano, Antonia [1 ]
Fanlo, Ana [1 ]
Martinez-Jarreta, Begona [3 ]
Sinues, Blanca [1 ]
机构
[1] Univ Zaragoza, Dept Pharmacol, Zaragoza 50009, Spain
[2] Cent Univ Ecuador, Fac Med Sci, Quito 170136, Ecuador
[3] Univ Zaragoza, Dept Legal Med, Zaragoza 50009, Spain
关键词
CYP2C8; CYP2C9; CYP2C19; Polymorphism; Spaniards; Ecuadorians; PROTON PUMP INHIBITORS; CYTOCHROME P4502C9; CYP2C19-ASTERISK-17; ALLELE; MUTANT ALLELES; METABOLISM; VARIANT; FREQUENCIES; PHARMACOKINETICS; VARIABILITY; CAUCASIANS;
D O I
10.1007/s11033-013-2971-y
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This study was designed to investigate the potential differences between Spaniards and Ecuadorian Mestizo people regarding CYP2C8, CYP2C9, and CYP2C19 genetic polymorphisms. DNA from 282 Spaniard and 297 Ecuadorian subjects were analyzed by either a previously reported pyrosequencing method (CY2C8*3, CYP2C9*2, CYP2C9*3, CYP2C19*2 and CYP2C19*3) or a nested PCR technique (CYP2C19*17). Whereas CYP2C19*17 allele distribution was higher in Ecuadorians than in Spaniards (P < 0.001) and the frequency of CYP2C19*3 was similar in these two populations (P > 0.05), the other allelic variants were detected at significantly lower frequencies in Ecuadorians than in Spaniards (P < 0.05). According to the diplotype distributions, the prevalence of the presumed CYP2C9 and CYP2C8 extensive metabolizers was higher in Ecuadorians than in Spaniards (P < 0.05). Individuals genotyped CYP2C19*1/*17 and *17/*17 who were considered as ultrarapid metabolizers were overrepresented in Ecuadorians in relation to Spaniards (P < 0.001). By contrast, among Ecuadorians no poor metabolizers (PMs) of either CYP2C8 or CYP2C9 were found and only two individuals were CYP2C19 PMs. These data are compatible with a higher CYP2C8, CYP2C9, and CYP2C19 activity in Mestizo Ecuadorians as opposed to Spaniards, which could imply differences in dosage requirements for drugs metabolized by these cytochromes and should also be considered in allele-disease association studies.
引用
收藏
页码:1267 / 1272
页数:6
相关论文
共 45 条
[1]  
Ali ZK, 2009, CURR OPIN DRUG DISC, V12, P108
[2]   CYP2C19 polymorphism and risk for essential tremor [J].
Alonso-Navarro, Hortensia ;
Martinez, Carmen ;
Garcia-Martin, Elena ;
Benito-Leon, Julian ;
Garcia-Ferrer, Isabel ;
Vazquez-Torres, Pilar ;
Puertas, Inmaculade ;
Lopez-Alburquerque, Tomas ;
Agundez, Jose A. G. ;
Jimenez-Jimenez, Felix Javier .
EUROPEAN NEUROLOGY, 2006, 56 (02) :119-123
[3]  
Arango J., 2004, Informe sobre la Situacion Demografica en Espana, P161
[4]   CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes [J].
Bahadur, N ;
Leathart, JBS ;
Mutch, E ;
Steimel-Crespi, D ;
Dunn, SA ;
Gilissen, R ;
Van Houdt, J ;
Hendrickx, J ;
Mannens, G ;
Bohets, H ;
Williams, FM ;
Armstrong, M ;
Crespi, CL ;
Daly, AK .
BIOCHEMICAL PHARMACOLOGY, 2002, 64 (11) :1579-1589
[5]   Increased omeprazole metabolism in carriers of the CYP2C19*17 allele;: a pharmacokinetic study in healthy volunteers [J].
Baldwin, R. Michael ;
Ohlsson, Staffan ;
Pedersen, Rasmus Steen ;
Mwinyi, Jessica ;
Ingelman-Sundberg, Magnus ;
Eliasson, Erik ;
Bertilsson, Leif .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 65 (05) :767-774
[6]  
Bernal ML, 1999, PHARMACOGENETICS, V9, P657, DOI 10.1097/01213011-199910000-00013
[7]   Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population:: an investigative and comparative study [J].
Bravo-Villalta, HV ;
Yamamoto, K ;
Nakamura, K ;
Bayá, A ;
Okada, Y ;
Horiuchi, R .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (03) :179-184
[8]   CYP2C9 allele frequency differences between populations of Mexican- Mestizo, Mexican- Tepehuano, and Spaniards [J].
Dorado, P. ;
Sosa-Macias, M. G. ;
Penas-LLedo, E. M. ;
Alanis-Banuelos, R. E. ;
Wong, M-L ;
Licinio, J. ;
Lares-Asseff, I. ;
LLerena, A. .
PHARMACOGENOMICS JOURNAL, 2011, 11 (02) :108-112
[9]   Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines [J].
Fukasawa, T. ;
Suzuki, A. ;
Otani, K. .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2007, 32 (04) :333-341
[10]  
Fukushima-Uesaka Hiromi, 2005, Drug Metab Pharmacokinet, V20, P300, DOI 10.2133/dmpk.20.300